33 
spokesperson for the major pharmaceutical, companies will be 
called upon to comment publicly about this new technology. The 
PMA should actively participate by testifying before Congress 
and setting forth in its testimony the recommendations made 
above. In addition, the PMA should develop and activate a 
low-key but deliberate and steady information effort to inform 
and educate policy-makers to understand and represent the 
pharmaceutical industry’s position. In addition, it should be 
prepared, as circumstances warrant, to do the same with 
interested media, religious and public interest groups. 
[ 634 ] 
